BridgeBio Pharma (BBIO) EBT Margin (2019 - 2026)
BridgeBio Pharma recorded quarterly EBT Margin of 57.91% in Q1 2026, up 54.15% quarter-over-quarter from 126.32% in Q4 2025, and up 4249.0% year-over-year from 1.33% in Q1 2025.
BridgeBio Pharma's EBT Margin history runs 8 years deep, the most recent figure standing at 57.91% for Q1 2026.
- In Q1 2026, EBT Margin rose 4249.0% year-over-year to 57.91%; the TTM figure through Mar 2026 stood at 116.48% (up 37258.0% YoY), while the FY2025 annual figure was 145.89%, up 9844.0% from the prior year.
- EBT Margin came in at 57.91% for Q1 2026 at BridgeBio Pharma, up from 126.32% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 9.02% in Q1 2024 to a low of 43350.3% in Q3 2022.
- A 5-year average of 6485.5% and a median of 4258.25% in 2023 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 3651019 bps in 2022 and jumped 3909205 bps in 2023, its largest moves.
- BridgeBio Pharma's EBT Margin stood at 7760.96% in 2022, then plunged by 42 bps to 11008.94% in 2023, then jumped by 59 bps to 4526.28% in 2024, then jumped by 97 bps to 126.32% in 2025, then soared by 54 bps to 57.91% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 57.91%, 126.32%, and 154.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -57.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.91% |
| Dec 31, 2025 | -126.32% |
| Sep 30, 2025 | -154.50% |
| Jun 30, 2025 | -164.30% |
| Mar 31, 2025 | -100.41% |
| Dec 31, 2024 | -4,526.28% |
| Sep 30, 2024 | -6,012.23% |
| Jun 30, 2024 | -3,484.50% |
| Mar 31, 2024 | -9.02% |
| Dec 31, 2023 | -11,008.94% |
| Sep 30, 2023 | -4,258.25% |
| Jun 30, 2023 | -9,882.94% |
| Mar 31, 2023 | -7,783.73% |
| Dec 31, 2022 | -7,760.96% |
| Sep 30, 2022 | -43,350.30% |
| Jun 30, 2022 | -135.18% |
| Mar 31, 2022 | -11,437.72% |
| Dec 31, 2021 | -1,805.66% |
| Sep 30, 2021 | -6,840.10% |
| Jun 30, 2021 | -1,229.78% |
| Mar 31, 2021 | -38,278.79% |
| Dec 31, 2020 | -113,117.21% |
| Sep 30, 2020 | -1,601.77% |
| Sep 30, 2019 | -201.91% |